Asabys Partners

Thrilled to announce that our portfolio company INBRAIN Neuroelectronics raised $50M Series B to accelerate the development of its graphene-based BCI-Tx platform, to decode and modulate neural activity with unprecedented resolution, and deliver personalized, adaptive treatments for conditions like Parkinson’s, epilepsy, and stroke rehabilitation.    Asabys Partners helped constitute and support INBRAIN back in 2020 in Barcelona, so we are extremely happy to welcome new investors who believe in the power of neural technologies such as imec.xpand, EIC Fund, Fond ICO Next Tech, CDTI-Innvierte and AVANÇSA   Congratulations Carolina Aguilar and Jose Antonio Garrido and the rest of INBRAIN's team! https://lnkd.in/d2CByKXY

We are excited to announce Agomab $89M Series D and warm welcome to the new investors Sanofi and The Invus Group.  We joined Agomab back in 2021, when the company acquired Asabys' portfolio company Origo Biopharma, and we have been supporting their work in the fields of fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis since then. https://lnkd.in/edyn9dAq

Exciting News from our Portfolio Company, Gradient Denervation Technologies! > Asabys is proud to announce that Stanton Rowe has joined Gradient’s board of directors. With a stellar track record in medtech, from early-stage startups to large corporations, Stanton will bring a wealth of expertise to the company. Welcome onboard, Stan! > We’re also celebrating FDA approval for the extension of Gradient’s early feasibility study-a testament to the incredible work of Gradient’s team over recent months. Huge congratulations to the Gradient team on these significant news! We’re excited to see the continued advancement of this breakthrough technology for patients in need.  Stanton Rowe, Martin Grasse, Asabys Partners, Sylvain Sachot, Isabel Jiménez Bernal

We are proud to announce that Maite Malet, our Investment & Corporate Development Director, will be speaking on a panel at #BioFuture2024! She will contribute her insights to discussions shaping the future of #healthcare, alongside industry leaders and pioneering companies. Don’t miss out on this opportunity to engage in conversations driving the next wave of breakthrough innovation. Register at www.BioFuture.com!

#EventoIQVIA: en el marco de nuestros encuentros #IQVIABreaktrough, este lunes celebramos el encuentro "Investing in Healthcare" donde abordamos las principales tendencias del sector, oportunidades de inversión y evolución del mercado #pharma en nuestro entorno. Y tuvimos la fortuna de contar con algunos de los principales expertos en estas materias, como Ana Azpeteguía de Neuraxpharm, Clara Campàs Moya de Asabys Partners, Joan Llansó Caldentey de Portobello Capital y Jose Maria Gonzalez Martinez, Senior Principal en #IQVIA. Algunas de las conclusiones más relevantes se basaron, por un lado, en una inminente reactivación del mercado, y por otro lado en el análisis de aquellas áreas donde se presentan más oportunidades a futuro, como las #CMOs (donde España puede convertirse en un HUB de producción) y el área de enfermedades #crónicas. Gracias por esta interesantísima jornada a todos.

Proud to see our portfolio company Medasense Biometrics Ltd. featured in Nature Magazine as the first device in the US health-care market designed to provide a quantitative assessment of pain. The intensity or nature of the pain experienced by patients is not reflected accurately nowadays, leading to misdiagnosis or inadequate treatment, since current pain scores are influenced by a multitude of factors, including a person’s medical history, gender, culture and emotional state. Many researchers aim to bring a level of objectivity to the diagnosis of pain, through devices designed to eliminate the social and individual variables that contribute to the current inaccuracies. 

I’ll be speaking on a panel at #BioFuture2024, New York City. Looking forward to connecting with industry leaders and innovative companies discussing the latest topics and trends shaping the future of healthcare.

Congratulations INBRAIN Neuroelectronics for successfully completing the world's first human graphene-based BCI procedure. This is a major achievement proving the power of graphene-based neural technologies in medicine. Bravo Carolina Aguilar, Kostas Kostarelos, Jose Antonio Garrido and the rest of the team!

Today we are excited to announce that we have successfully closed the Sabadell Asabys Health Innovation Investments II (SAHII II) fund with total commitments of €180M, surpassing our initial target of €150M. Our second fund will invest in 12-15 companies across biopharma, medtech, and digital health, focusing on solutions for unmet medical needs and improving patient outcomes. Key details: ● Fund II already invested in 5 companies so far: deepull, Orikine Bio, Gradient Denervation Technologies, ALLOX and Augustine Therapeutics. ● SAHII II welcomes new US and international investors, as well as recurring investors from SAHII I such as Banco Sabadell, European Investment Fund (EIF), Alantra. ● To date, Asabys raised close to €300M in AUM, invested in 17 companies since its inception in 2018. Our team of 11 professionals, supported by venture partners and advisors, is committed to investing in life sciences companies developing novel solutions for unmet medical needs building on solid scientific evidence and a clear benefit for patients. https://lnkd.in/ds-xsx7X #SAHII #Biopharma #Medtech #LifeSciences

Excited to share that our Managing Partner, Clara Campàs Moya, will be part of the panel “Investing in Healthcare”, organized by SpainCap and IQVIA next 30th. Sep in Madrid, where she’ll share her insights on innovation and investment strategies within the venture capital sector. It’s an exciting opportunity to shape the future of healthcare and investment. #VentureCapital #Healthcareinvestment